This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Masimo's (MASI) iSirona to Boost Hospital Automation Platform
by Zacks Equity Research
Masimo's (MASI) iSirona helps in efficient workflow in hospitals by providing continuous connectivity, thereby helping clinicians to improve patient outcomes.
Masimo (MASI) Reports Encouraging 2020 Preliminary Results
by Zacks Equity Research
Per the preliminary announcement, Masimo (MASI) projects 2020 product revenues to improve.
Digital Health M&As Gain Precedence in the New Normal
by Debanjana Dey
The booming digital health space has been witnessing significant M&A activities amid the pandemic.
Masimo's (MASI) Telehealth Solution Helps in COVID-19 Crisis
by Zacks Equity Research
Masimo (MASI) is lending support to Renown Health through Masimo SafetyNet in order to manage the COVID-19 surge.
Masimo (MASI) Releases Favorable Findings on Pulse Oximetry
by Zacks Equity Research
Researchers on probe discover that the use of Masimo's (MASI) SpHb was related to the lower rate of postoperative transfusion, minimal duration of ICU stay and other better outcomes.
Masimo (MASI) Earnings and Revenues Beat Estimates in Q3
by Zacks Equity Research
Masimo (MASI) continues to gain from key Product segment, which witnessed solid growth in Q3.
Masimo (MASI) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Masimo (MASI) delivered earnings and revenue surprises of 42.86% and 1.13%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
ABIOMED (ABMD) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
The full commercial launch of Impella 5.5 in May is expected to have contributed to ABIOMED's (ABMD) fiscal second-quarter results
Quidel (QDEL) to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
Quidel (QDEL) is likely to have witnessed an uptick in rapid immunoassay revenues in Q3.
DaVita (DVA) to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
Solid performance by the net dialysis and related lab patient service segment is likely to have contributed to DaVita's (DVA) top line in the third quarter.
Varian (VAR) to Report Q4 Earnings: What's in the Offing?
by Zacks Equity Research
Varian's (VAR) solid Oncology platform is expected to have driven fiscal fourth-quarter performance.
Cerner (CERN) to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
Cerner's (CERN) third-quarter results are likely to reflect solid show by Subscriptions and Managed Services segments.
PerkinElmer (PKI) to Post Q3 Earnings: What's in the Offing?
by Zacks Equity Research
PerkinElmer's (PKI) third-quarter results are likely to reflect strong performance at Diagnostics segment.
DexCom (DXCM) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
DexCom's (DXCM) third-quarter results are likely to reflect rising global awareness of its real-time CGM.
Masimo (MASI) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Masimo (MASI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Aphria (APHA) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Aphria's (APHA) fiscal first-quarter results are likely to reflect higher sales from medical and adult-use cannabis products.
Why Masimo (MASI) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Masimo (MASI) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
What's in Store for Intuitive Surgical's (ISRG) Q3 Earnings?
by Zacks Equity Research
Intuitive Surgical's (ISRG) third-quarter earnings are likely to reflect weaker-than-expected performance at Instruments & Accessories segment.
3 Large-Cap MedTech Growth Stocks to Buy Amid the Pandemic
by Sriparna Ghosal
Let's take a look at three large-cap MedTech stocks that are currently flourishing on the back of a number of positive developments.
Masimo Unveils New Wearable Wireless Continuous Thermometer
by Zacks Equity Research
Masimo's (MASI) wearable wireless continuous thermometer offers consumers hassle-free continuous body temperature measurements, thereby eliminating the need for manual measurements.
Masimo's (MASI) Rad-G Pulse Oximeter Receives FDA Clearance
by Zacks Equity Research
Masimo's (MASI) Rad-G Pulse Oximeter receives FDA clearance, thereby allowing clinicians to access the most accurate and reliable pulse oximetry monitoring technologies.
Masimo's (MASI) O3 Regional Oximetry Attains FDA Approval
by Zacks Equity Research
Masimo's (MASI) O3 Regional Oximetry's FDA clearance can help clinicians offer quick and accurate care
Masimo (MASI) Down 0.3% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Masimo (MASI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Masimo Releases Favorable Study Results on Pulse Oximetry
by Zacks Equity Research
The pulse oximetry study result should be a major breakthrough for Masimo (MASI) to capture the neonatal patient care market.
Masimo PVi Gets FDA Approval to Measure Fluid Responsiveness
by Zacks Equity Research
The FDA approval of Masimo's (MASI) PVi system will enable patient safety.